FDA partners with university on biopharmaceutical manufacturing

Published: 14-Aug-2019
Regulatory Pharmaceutical

Delaware University and the FDA will have the ability to collaborate in a pre-competitive environment

The National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) announced that the University of Delaware (US), on behalf of NIIMBL, has entered into a Collaborative Research and Development Agreement (CRADA) with the Food and Drug Administration (FDA). The FDA and NIIMBL will have the ability to collaborate in a pre-competitive environment to strengthen research, innovation, training, and collaboration in the biopharmaceutical manufacturing industry.

"We are increasingly seeing the potential for advanced manufacturing innovations that can improve drug quality, help address shortages of medicines, speed time-to-market, and support personalised medicine through technologies including 3D printing and continuous manufacturing," said Acting FDA Commissioner, Ned Sharpless. "These technologies can also help the US prepare for public health emergencies by rapidly scaling manufacturing capabilities for vaccines and other medical countermeasures. FDA is taking many steps, including this public-private partnership with NIIMBL, to encourage and help realize the potential of advanced manufacturing: issuing guidance on emerging technologies, approving products made with these technologies, and advancing regulatory science."

This CRADA will enable FDA and NIIMBL to support investments in regulatory science research and training needed to foster advanced manufacturing innovations in areas such as continuous manufacturing, on-demand manufacturing, and advanced process control technologies, among others. Ultimately, advancements in these areas will help increase NIIMBL's national impact by enhancing patient access to new and improved medicines.

"Biopharmaceuticals are more challenging to manufacture than traditional pharmaceuticals and NIIMBL seeks to enhance patient access by innovating the biopharmaceutical manufacturing technologies and processes. This CRADA establishes a framework for FDA engagement in NIIMBL projects and initiatives that strengthens the existing NIIMBL-FDA relationship and supports the development of advanced biopharmaceutical manufacturing innovations," says Kelvin Lee, NIIMBL Institute Director.

  • Companies:
  • US Food and Drug Administration (FDA)
  • The National Institute for Innovation in Manufacturing Biopharmaceutic
See more

You may also like

Regulatory

Interview with FDA Press Officer Charles Kohler from CDER

Read more
The FDA Press Officer from CDER talks about how to navigate the compliance pathways for those in the pharmaceutical industry. Written by Tom McGhie from Cleanroom Technology

Trending Articles

  1. What is ISO 8 cleanroom classification? Each cleanroom class is denoted by a maximum concentration of particles per cubic meter or cubic foot of air. ISO 8 is the second lowest cleanroom classification
  2. Impact of the new Annex 1 on sterile filling in pharma EU GMP Annex 1 is a whole new era for the sterile filling industry. From barrier technology to “first air”, pharmaceutical manufacturers have a lot to decide. Johannes Rauschnabel from Syntegon discusses how equipment suppliers can help with implementation
  3. Thermo Fisher Scientific opens sterile drug facility in Asia The global company has built a new manufacturing facility and expanded capabilities in Singapore to enable the country’s science and technology sector to accelerate research, development and manufacturing of critical medicines and vaccines
  4. Recce Pharmaceuticals transfers equipment to third party cleanroom for special batch The Australia-based company developing a new class of synthetic anti-infectives has sourced a larger third party cleanroom due to increased demand for its product to fight antimicrobial resistance

Upcoming event

Lounges

23-25 April 2024 | Conference | Messe Karlsruhe, Germany See all

You may also like

Regulatory

Interview with FDA Press Officer Charles Kohler from CDER

The FDA Press Officer from CDER talks about how to navigate the compliance pathways for those in the pharmaceutical industry. Written by Tom McGhie from Cleanroom Technology
Regulatory

FDA Warning Letter: ImprimisRx facility features stained HEPA filters

Following a 2022 inspection, ophthalmic medicine production expert ImprimisRx received a 483 form. A year later a warning letter has been sent emphasising major issues with the facility design and operation
Regulatory

Warning Letters: Lessons from an FDA Captain

Redica Systems’ Jerry Chapman talks to FDA's Ileana Barreto-Pettit
Regulatory

Abraxis Bioscience receives FDA warning

During the examination, FDA officials found that the company “failed to thoroughly investigate any unexplained discrepancy or failure of a batch”
Regulatory

FDA gives out 483 form to Torrent Pharma citing "inadaquate cleaning procedure"

The pharma giant from India has been give the form citing three main issues
Cleaning

Study finds $1 per reaction LAMP assay works for BCC testing

The novel assay has been assessed for detecting the bacteria responsible for many pharmaceutical product recalls, Burkholderia cepacia complex
Regulatory

Strides Pharma passes US FDA inspection at Singapore facility

The global pharma company has completed the inspection with zero 483 observations
Subscribe now